Market Overview

Jefferies Upgrades Nanosphere to Buy

Related NSPH
Morning Market Movers
Morning Market Movers

Molecular diagnostics developer Nanosphere (NASDAQ: NSPH) was upgraded from Hold to buy at Jefferies & Company on Tuesday.

Jefferies said in the research report that, "We are upgrading NSPH to Buy (from Hold) on expectations for its recently FDA approved gram-positive blood stream infection test to drive a significant acceleration in new system placements & revenue. We are raising our 2012 & 2013 revenue forecasts to $9.5M (from $9M) and $28M (from $20M), respectively. Our PT moves to $5 (from $2) on higher cash flow forecasts."

Nanosphere reported on June 27 that it had received the FDA authorization to market its Gram-Positive Blood Culture Test, stating that "the BC-GP test notably expands Nanosphere's infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat."

“With the BC-GP test, patients suspected of deadly infections can now get a first-ever diagnostic tool for detecting disease-causing bacteria while simultaneously determining antibiotic resistance within the critical timeframe for making and adjusting initial treatment," said William Moffitt, Nanosphere's Chief Executive Officer.

On Tuesday, Nanosphere traded at about $3.20, up roughly 27.8 percent.

Follow me @BCallwood.

Stock chart: 
Stock chart

Posted-In: Analyst Color News Upgrades Price Target FDA Management Analyst Ratings Movers Best of Benzinga

 

Most Popular

Related Articles (NSPH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free